Natera, Inc. (NASDAQ:NTRA) Shares Sold by FDx Advisors Inc.

FDx Advisors Inc. reduced its position in Natera, Inc. (NASDAQ:NTRA) by 33.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,483 shares of the medical research company’s stock after selling 1,224 shares during the quarter. FDx Advisors Inc.’s holdings in Natera were worth $393,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Blue Trust Inc. grew its holdings in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd increased its position in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. Principal Securities Inc. increased its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares during the period. Finally, True Wealth Design LLC acquired a new stake in shares of Natera in the third quarter valued at $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of Natera stock opened at $168.19 on Friday. The company’s fifty day moving average is $168.06 and its two-hundred day moving average is $144.78. Natera, Inc. has a 1 year low of $69.14 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Insider Buying and Selling

In related news, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 295,772 shares of company stock valued at $49,741,699 over the last quarter. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

NTRA has been the topic of several recent research reports. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Barclays assumed coverage on shares of Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Piper Sandler lifted their price objective on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Finally, TD Cowen lifted their price target on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $170.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.